Abstract 7302: A Novel Therapeutic Approach : New Drug Candidate with are potent and safe next-generation multi-target immune checkpoint inhibitor

Abstract Immune checkpoint inhibitors play a crucial role in current cancer treatments, serving as promising therapeutic options across various cancer types. In particular, PD-L1/PD-1 immune checkpoint inhibitors have been at the forefront of this field. However, recent concerns have been raised regarding the risk-benefit ratio of treatment based on PD-L1 expression levels, prompting the need for the development of immune checkpoint therapies that demonstrate high efficacy regardless of whether PD-L1 expression is high or low. Cellemedy’s T-sphaera platform based multi-target immune checkpoint inhibitors that simultaneously act on multiple immune targets, regardless of target expression levels. This platform offers several advantages: 1) it introduces biologically active domains that exhibit therapeutic effects, 2) it demonstrates high avidity based on protein structural characteristics, 3) it inherently possesses a cancer-T cell engaging effect when introducing multi-targets, and 4) being human protein-based results in reduced immune-related side effects, contributing to a favorable safety profile and therapeutic index. Cellemedy’s multi-target immune checkpoint inhibitors exhibit target-specific cytotoxicity against melanoma cancer cell line. In a non-human toxicity study, those compounds were well tolerated during repeated dosing, providing evidence of a superior safety profile without noticeable side effects. Furthermore, we verified strong efficacy in in vivo studies through T/NK cell engagement and high target avidity following a single-dose administration. Rapid and durable anti-tumor responses have been observed in vivo models. In summary, Cellemedy’s T-sphaera is promising multi-target immune checkpoint inhibitor platform that can be designed for various target, not only immune checkpoint blockade but also other tumor receptors, aiming at multiple cancers. Citation Format: Bo-Ram Lee, Seon-Boon Lee, Chul Joo Yoon, Hyunju Hwang, Sunho Jung, Joon Heo, Kyung-Mi Lee, H. Chris Kim. A Novel Therapeutic Approach : New Drug Candidate with are potent and safe next-generation multi-target immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7302.